Molecular Profiling of Gliomas: Implications for Prognosis and Treatment

This lecture is designed to help physicians implement evidence-based strategies for patients with gliomas. This course may be of special interest to physicians in the fields of neurology, neurocritical care and emergency medicine, along with other physicians interested in identifying predictive biomarkers or molecular actionable targets that are paving the way to molecular-based targeted therapies.

Target Audience

Neurologists, Neuro-Oncologists, Stroke Neurologists, Neuroradiologists, Diagnostic Radiologists, Radiation Oncologists, Critical Care Physicians, Neurointensivists, Emergency Medicine Physicians, Internal Medicine Physicians, Interventional Neuroradiologists, Family Physicians, General Internists, Neuropsychologists, Physician Assistants and Fellows.

Learning Objectives

  • Analyze the updated classification of diffuse gliomas.
  • Evaluate the frequency and prognostic implications of molecular profiles in gliomas.
  • Examine the advances in treatment modalities and relation to molecular profiles.
Additional information
Bibliography: 
  • Alentorn, Agusti, et al. "Molecular profiling of gliomas: potential therapeutic implications." Expert review of anticancer therapy 15.8 (2015): 955-962.
  • Wang M, Cairncross G, Shaw E et al. Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402. International Journal of Radiation Oncology*Biology*Physics 77(3), 662-669 (2010).
  • Van Den Bent MJ, Brandes AA, Taphoorn MJB et al. Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology 31(3), 344-350 (2013). 
  • Cairncross G, Wang M, Shaw E et al. Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. Journal of Clinical Oncology 31(3), 337-343 (2013).
  • Gorlia T, Delattre J-Y, Brandes AA et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European Journal of Cancer 49(16), 3477-3485 (2013).
Resources: 
Patient Resources

Stroke education for patients and their families. 

 

Course Summary
Available credit: 
  • 0.75 ABIM MOC II
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 General certificate of attendance
Course opens: 
03/07/2017
Course expires: 
03/07/2018

Yazmin Odia, M.D., M.S.
Neuro-Oncologist
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida

Yazmin Odia, M.D., M.S., indicated that neither she nor her spouse/partner has relevant financial relationships with commercial interest companies, and she will not include off-label or unapproved product usage in her presentations or discussions. 

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose. 

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
             
Baptist Health South Florida designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC  

Successful completion of this CME activity enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Your participation information will be shared with the ACCME, which will in turn report your points to ABIM. Successful completion of a course examination is required to earn ABIM MOC points.

Available Credit

  • 0.75 ABIM MOC II
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 General certificate of attendance
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

This site is best viewed on the two most recent stable releases of the following browsers for all public pages:

PCs Running Windows

  • Google Chrome (Preferred): Download free web browser for PC, Mac, phone and tablet. 
  • Internet Explorer (IE 11 and above recommended): You will be prompted to download videos before you are able to view. Click “download” to view video.  After a momentary pause, the recording will play. 
  • Mozilla Firefox: You may be prompted under the “This Connection is Untrusted” screen to add “cmeonline.baptisthealth.net” and “cdn.baptisthealth.net” under “add exceptions”.

Apple Computers Running OSX

  • Google Chrome (Preferred): Download free web browser for PC, Mac, phone and tablet. 
  • Safari
  • Mozilla Firefox: You may be prompted under the “This Connection is Untrusted” screen to add “cmeonline.baptisthealth.net” and “cdn.baptisthealth.net” under “add exceptions”.

This site uses a responsive design, which allows the page layout of elements to change depending on the screen resolution. Certain functionality may change based on the screen resolution of smaller screens, such as the number of columns in a table.

Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.